SureNano Science's GEP-44 Program Signals Next-Generation GLP-1 Innovation in Obesity and Metabolic Disease Treatment

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has been featured in a BioMedWire editorial that examines the evolution of GLP-1 therapies and the emerging innovation in obesity and metabolic disease treatment. The editorial highlights SureNano's subsidiary GlucaPharm Inc. and its GEP-44 program, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in the rapidly expanding GLP-1 market. As demand continues to grow for next-generation therapies targeting obesity, type 2 diabetes and related chronic conditions, GEP-44 represents a potential advancement in addressing these global health challenges.

According to the editorial, GLP-1 receptor agonists have revolutionized the treatment of type 2 diabetes and obesity, but limitations such as gastrointestinal side effects and the need for injectable delivery remain. SureNano's GEP-44 is a triple agonist peptide that targets GLP-1, GIP, and glucagon receptors, potentially offering enhanced weight loss and glycemic control with improved tolerability. The program also explores non-injectable delivery routes, which could significantly improve patient compliance and access.

SureNano Science Ltd. is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets. The company has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery (refer to press release dated February 23, 2026). The initial business of SureNano Science Ltd. is the sale and distribution of the SureNano(TM) surfactant, a ready-to-mix food grade compound that provides the base for high performance nanoemulsions. The company is now developing into a pharmaceutical-focused company through the advancement of this patented therapeutic candidate.

The BioMedWire editorial underscores the importance of innovation in the GLP-1 space, as the market is projected to reach tens of billions of dollars in the coming years. SureNano's GEP-44 program could position the company as a key player in this competitive landscape, particularly if it successfully demonstrates superior efficacy and tolerability in clinical trials. The editorial also notes that the ability to deliver GLP-1 therapies via non-injectable routes could address a significant unmet need, as many patients prefer oral or other less invasive options.

For more information on SureNano Science Ltd., visit the company's newsroom at https://ibn.fm/SURNF. To view the full press release, visit https://ibn.fm/AGdi9.